Role of Microbiome in the Realm of Immune Checkpoint Inhibitor Induced GI Complications in the Cancer Population (Phase I)

All Cancers
Active Trial
Yinghong Wang, MD
The University of Texas MD Anderson Cancer Center

Summary:

Dr. Linehan’s trial is examining the use of a dual immunotherapy approach in combination with standard chemotherapy to treat inoperable and locally advanced pancreatic ductal cancer (PDAC). The dual immunotherapy drugs, nivolumab and pepinemab, will activate the immune system to fight against the pancreatic tumors thereby enhancing the effectiveness of the chemotherapy folfirinox in targeting and eradicating the tumor cells. If successful, this trial will result in a new, more effective treatment approach for patients diagnosed with PDAC.